NASDAQ:CFRX
$2.08
(
8.33%
)
Friday, 24th Mar 2023
ContraFect Corporation Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $1.75 | $6.95 | Friday, 24th Mar 2023 CFRX stock ended at $2.08. This is 8.33% more than the trading day before Thursday, 23rd Mar 2023. During the day the stock fluctuated 13.16% from a day low at $1.90 to a day high of $2.15. |
| 90 days | $0.0586 | $6.95 | |
| 52 weeks | $0.0586 | $6.95 |
Historical ContraFect Corporation prices
| Date | Open | High | Low | Close | Volume |
| 2023-03-24 | $1.92 | $2.15 | $1.90 | $2.08 | 121 635 |
| 2023-03-23 | $1.94 | $2.00 | $1.91 | $1.92 | 11 635 |
| 2023-03-22 | $2.00 | $2.11 | $1.94 | $1.99 | 102 243 |
| 2023-03-21 | $1.81 | $2.09 | $1.80 | $2.00 | 152 455 |
| 2023-03-20 | $1.86 | $1.99 | $1.75 | $1.79 | 76 557 |
| 2023-03-17 | $2.00 | $2.09 | $1.76 | $1.91 | 156 015 |
| 2023-03-16 | $2.05 | $2.12 | $1.94 | $2.02 | 80 034 |
| 2023-03-15 | $2.27 | $2.28 | $2.00 | $2.09 | 125 506 |
| 2023-03-14 | $2.16 | $2.35 | $2.16 | $2.24 | 130 653 |
| 2023-03-13 | $2.18 | $2.25 | $2.06 | $2.15 | 104 505 |
| 2023-03-10 | $2.35 | $2.35 | $2.15 | $2.19 | 121 036 |
| 2023-03-09 | $2.56 | $2.62 | $2.29 | $2.34 | 199 151 |
| 2023-03-08 | $2.77 | $2.82 | $2.52 | $2.56 | 99 255 |
| 2023-03-07 | $2.83 | $3.27 | $2.67 | $2.80 | 428 623 |
| 2023-03-06 | $3.07 | $3.12 | $2.82 | $2.85 | 198 899 |
| 2023-03-03 | $2.99 | $3.34 | $2.89 | $3.15 | 230 445 |
| 2023-03-02 | $3.03 | $3.11 | $2.87 | $2.99 | 181 758 |
| 2023-03-01 | $3.45 | $3.46 | $3.11 | $3.15 | 137 978 |
| 2023-02-28 | $3.45 | $3.70 | $3.16 | $3.47 | 1 010 208 |
| 2023-02-27 | $6.20 | $6.95 | $4.61 | $4.74 | 27 134 778 |
| 2023-02-24 | $3.27 | $3.30 | $3.02 | $3.10 | 66 615 |
| 2023-02-23 | $3.22 | $3.33 | $3.05 | $3.30 | 93 319 |
| 2023-02-22 | $3.30 | $3.32 | $3.04 | $3.22 | 123 618 |
| 2023-02-21 | $3.60 | $3.73 | $3.27 | $3.35 | 147 783 |
| 2023-02-17 | $3.89 | $4.15 | $3.60 | $3.63 | 247 099 |
| 2023-02-16 | $3.95 | $4.90 | $3.86 | $4.03 | 464 379 |
| 2023-02-15 | $4.59 | $4.59 | $3.83 | $4.02 | 411 560 |
| 2023-02-14 | $0.0637 | $0.0726 | $0.0610 | $0.0630 | 13 392 653 |
| 2023-02-13 | $0.0625 | $0.0660 | $0.0605 | $0.0644 | 4 556 718 |
| 2023-02-10 | $0.0616 | $0.0715 | $0.0590 | $0.0669 | 11 687 652 |
| 2023-02-09 | $0.0656 | $0.0656 | $0.0603 | $0.0625 | 7 548 536 |
| 2023-02-08 | $0.0640 | $0.0669 | $0.0613 | $0.0660 | 4 560 184 |
| 2023-02-07 | $0.0704 | $0.0704 | $0.0640 | $0.0673 | 8 124 311 |
| 2023-02-06 | $0.0700 | $0.0720 | $0.0681 | $0.0700 | 7 193 325 |
| 2023-02-03 | $0.0695 | $0.0718 | $0.0680 | $0.0696 | 8 264 458 |
| 2023-02-02 | $0.0675 | $0.0728 | $0.0667 | $0.0695 | 12 623 492 |
| 2023-02-01 | $0.0708 | $0.0715 | $0.0660 | $0.0710 | 15 579 319 |
| 2023-01-31 | $0.0795 | $0.0849 | $0.0682 | $0.0750 | 85 163 361 |
| 2023-01-30 | $0.0652 | $0.0695 | $0.0586 | $0.0614 | 22 902 667 |
| 2023-01-27 | $0.0739 | $0.0740 | $0.0631 | $0.0685 | 41 077 423 |
| 2023-01-26 | $0.0950 | $0.101 | $0.0910 | $0.0921 | 20 980 835 |
| 2023-01-25 | $0.113 | $0.120 | $0.0950 | $0.100 | 34 108 074 |
| 2023-01-24 | $0.0949 | $0.120 | $0.0906 | $0.119 | 73 541 826 |
| 2023-01-23 | $0.0933 | $0.0960 | $0.0880 | $0.0906 | 22 773 779 |
| 2023-01-20 | $0.107 | $0.107 | $0.0830 | $0.0910 | 92 497 583 |
| 2023-01-19 | $0.0910 | $0.100 | $0.0860 | $0.0940 | 17 318 800 |
| 2023-01-18 | $0.0990 | $0.0990 | $0.0890 | $0.0910 | 5 300 200 |
| 2023-01-17 | $0.101 | $0.104 | $0.0943 | $0.0954 | 5 225 604 |
| 2023-01-13 | $0.100 | $0.105 | $0.0954 | $0.101 | 6 117 366 |
| 2023-01-12 | $0.109 | $0.109 | $0.0950 | $0.0990 | 5 946 200 |
About ContraFect Corporation
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the in... CFRX Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
